Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Alexander M. Menzies; M. T. Ashworth; S. Swann; R. F. Kefford; K. Flaherty; J. Weber; J. R. Infante; K. B. Kim; R. Gonzalez; O. Hamid; L. Schuchter; J. Cebon; J. A. Sosman; S. Little; P. Sun; G. Aktan; D. Ouellet; F. Jin; G. V. Long; A. Daud

doi:10.1093/annonc/mdu529

Characteristics of pyrexia in BRAF^V600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Alexander M. Menzies, M. T. Ashworth, S. Swann, R. F. Kefford, K. Flaherty, J. Weber, J. R. Infante, K. B. Kim, R. Gonzalez, O. Hamid, L. Schuchter, J. Cebon, J. A. Sosman, S. Little, P. Sun, G. Aktan, D. Ouellet, F. Jin, G. V. Long, A. Daud

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug efficacy. The etiology is unclear but may involve drug exposure. This requires further research, as do strategies to prevent recurrent pyrexia.

Original language	English (US)
Pages (from-to)	415-421
Number of pages	7
Journal	Annals of Oncology
Volume	26
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdu529
State	Published - Feb 1 2015

Keywords

BRAF
Dabrafenib
Fever
Melanoma
Pyrexia
Trametinib

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdu529

Cite this

Menzies, A. M., Ashworth, M. T., Swann, S., Kefford, R. F., Flaherty, K., Weber, J., Infante, J. R., Kim, K. B., Gonzalez, R., Hamid, O., Schuchter, L., Cebon, J., Sosman, J. A., Little, S., Sun, P., Aktan, G., Ouellet, D., Jin, F., Long, G. V., & Daud, A. (2015). Characteristics of pyrexia in BRAF^V600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology, 26(2), 415-421. https://doi.org/10.1093/annonc/mdu529

@article{a60afe5aefe845e5939efe4341d2e143,

title = "Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial",

abstract = "Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug efficacy. The etiology is unclear but may involve drug exposure. This requires further research, as do strategies to prevent recurrent pyrexia.",

keywords = "BRAF, Dabrafenib, Fever, Melanoma, Pyrexia, Trametinib",

author = "Menzies, {Alexander M.} and Ashworth, {M. T.} and S. Swann and Kefford, {R. F.} and K. Flaherty and J. Weber and Infante, {J. R.} and Kim, {K. B.} and R. Gonzalez and O. Hamid and L. Schuchter and J. Cebon and Sosman, {J. A.} and S. Little and P. Sun and G. Aktan and D. Ouellet and F. Jin and Long, {G. V.} and A. Daud",

year = "2015",

month = feb,

day = "1",

doi = "10.1093/annonc/mdu529",

language = "English (US)",

volume = "26",

pages = "415--421",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "2",

}

Menzies, AM, Ashworth, MT, Swann, S, Kefford, RF, Flaherty, K, Weber, J, Infante, JR, Kim, KB, Gonzalez, R, Hamid, O, Schuchter, L, Cebon, J, Sosman, JA, Little, S, Sun, P, Aktan, G, Ouellet, D, Jin, F, Long, GV & Daud, A 2015, 'Characteristics of pyrexia in BRAF^V600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial', Annals of Oncology, vol. 26, no. 2, pp. 415-421. https://doi.org/10.1093/annonc/mdu529

TY - JOUR

T1 - Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

AU - Menzies, Alexander M.

AU - Ashworth, M. T.

AU - Swann, S.

AU - Kefford, R. F.

AU - Flaherty, K.

AU - Weber, J.

AU - Infante, J. R.

AU - Kim, K. B.

AU - Gonzalez, R.

AU - Hamid, O.

AU - Schuchter, L.

AU - Cebon, J.

AU - Sosman, J. A.

AU - Little, S.

AU - Sun, P.

AU - Aktan, G.

AU - Ouellet, D.

AU - Jin, F.

AU - Long, G. V.

AU - Daud, A.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug efficacy. The etiology is unclear but may involve drug exposure. This requires further research, as do strategies to prevent recurrent pyrexia.

AB - Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug efficacy. The etiology is unclear but may involve drug exposure. This requires further research, as do strategies to prevent recurrent pyrexia.

KW - BRAF

KW - Dabrafenib

KW - Fever

KW - Melanoma

KW - Pyrexia

KW - Trametinib

UR - http://www.scopus.com/inward/record.url?scp=84923927971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923927971&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu529

DO - 10.1093/annonc/mdu529

M3 - Article

C2 - 25411413

AN - SCOPUS:84923927971

SN - 0923-7534

VL - 26

SP - 415

EP - 421

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -